Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
Abstract
Authors
S. Djalalov J. Beca J.S. Hoch M.D. Krahn M.S. Tsao J.C. Cutz N. Leighl